Spotlight On... Pulmatrix taps Capsugel for R&D, manufacturing; Genomics firm raises $45M; and much more...

Capsugel and Pulmatrix ($PULM) have teamed up to develop new inhaled therapies for COPD, cystic fibrosis and idiopathic pulmonary fibrosis. News

> Cambridge, MA's Seven Bridges raised $45 million to support its large-scale genomics platform. More

> Drugmaker Athenex is planning to build a manufacturing plant in New York after securing a $225 million investment from the state. Item

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.